Novo Nordisk A/S (NYSE:NVO) Shares Sold by Financial Insights Inc.

Financial Insights Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,072 shares of the company’s stock after selling 140 shares during the period. Financial Insights Inc.’s holdings in Novo Nordisk A/S were worth $247,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. RMR Wealth Builders acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $302,000. Future Financial Wealth Managment LLC acquired a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $128,000. Sunpointe LLC lifted its stake in shares of Novo Nordisk A/S by 5.8% in the 1st quarter. Sunpointe LLC now owns 6,757 shares of the company’s stock worth $874,000 after acquiring an additional 372 shares during the period. DGS Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 2.8% in the 1st quarter. DGS Capital Management LLC now owns 42,888 shares of the company’s stock worth $5,507,000 after acquiring an additional 1,151 shares during the period. Finally, S.A. Mason LLC lifted its stake in shares of Novo Nordisk A/S by 33.7% in the 1st quarter. S.A. Mason LLC now owns 9,628 shares of the company’s stock worth $1,236,000 after acquiring an additional 2,428 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 0.7 %

NVO stock opened at $116.46 on Wednesday. Novo Nordisk A/S has a 52-week low of $92.94 and a 52-week high of $148.15. The company’s 50 day simple moving average is $127.89 and its 200-day simple moving average is $131.61. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $522.62 billion, a P/E ratio of 39.88, a P/E/G ratio of 1.54 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion for the quarter, compared to analyst estimates of $9.91 billion. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is currently 24.66%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on NVO. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.